argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
19 aug 2014 - 13:53
Statutaire naam
argenx SE
Titel
arGEN-X announces positive preclinical results for ARGX-113
Bericht
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
arGEN-X announces positive preclinical results for ARGX-113
Data support ARGX-113 as a potential breakthrough concept for management of flares in severe autoimmune diseases
19 August 2014
Breda, the Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today the results of a preclinical study assessing the ph
Gerelateerde downloads
Datum laatste update: 23 april 2025